SML2694
FB23-2
≥98% (HPLC)
Synonym(s):
2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxybenzamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C18H15Cl2N3O3
CAS Number:
Molecular Weight:
392.24
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
ClC1=C(NC2=C(C(NO)=O)C=CC=C2)C(Cl)=CC(C3=C(C)ON=C3C)=C1
Biochem/physiol Actions
FB23-2 can also prevent osteogenic differentiation of human mesenchymal stem cells (MSCs). It is capable of delaying leukemogenesis in vivo. In mice, FB23-2 at a dose of 20 mg/kg is safe for testing in vivo efficacy.
FB23-2 is a cell penetrant, potent and specific inhibitor of N6-methyladenosine (m6A) demethylase FTO (fat mass and obesity associated protein) that RNA methylation in varies of AML cells. FB23-2 potently inhibits proliferation and promotes apoptosis and differentiation in human acute myeloid leukemia (AML) cells and primary blast AML cells lines and xenografts in mice. It minimally affects proliferation of human normal bone marrow cells.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yue Huang et al.
Cancer cell, 35(4), 677-691 (2019-04-17)
FTO, an mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's m6A demethylase activity. Mimicking FTO
The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG.
Liu-Shan Chen et al.
Acta pharmacologica Sinica, 43(5), 1311-1323 (2021-09-01)
N6-methyladenosine (m6A) is the most abundant posttranscriptional methylation modification that occurs in mRNA and modulates the fine-tuning of various biological processes in mammalian development and human diseases. In this study we investigated the role of m6A modification in the osteogenesis
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service